NCT05576012View on ClinicalTrials.gov

First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

SOL-116

Participants will receive SC injection in a double-blind manner

BIOLOGICAL

Placebo

Participants will receive SC injection in a double-blind manner

Trial Locations (2)

Unknown

QPS Netherlands B.V., Groningen

CHDR (Stichting Centre for Human Drug Research), Leiden

Sponsors

Lead Sponsor

Lipum AB
All Listed Sponsors
collaborator

QPS Netherlands B.V.

INDUSTRY

lead

Lipum AB

INDUSTRY